Multiple myeloma can be staged in terms of severity by using ancillary test results such as hemoglobin, serum calcium, bone x-rays, and serum myeloma protein production rate. Multiple myeloma is often staged by adjunctive findings such as hemoglobin to determine the severity of multiple myeloma. Traditionally, stage I is defined as those who meet the criteria of hemoglobin >100 g/l; serum calcium ≤2.65 mmol/l; normal bone structure or isolated plasmacytoma of bone on skeletal X-ray; and low serum or urinary myeloma protein production rate. Stage II is between stages I and III. Stage III criteria are hemoglobin <85 g/l or serum calcium >2.65 mmol/l or skeletal examination suggestive of >3 osteolytic lesions or high serum or urinary myeloma protein production. Stage I of RI-ISS staging also includes non-cytogenetic high-risk patients with normal LDH levels; stage III patients with cytogenetic high-risk patients or with higher than normal LDH levels. If there is any discomfort, it is recommended to go to the hematology department of the hospital in time for diagnosis and treatment.